Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;7(3):104-109.
doi: 10.14740/cr468w. Epub 2016 Jun 24.

Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment

Viviane Gouveia  1 , Dinaldo C Oliveira  1 , Emmanuele Tenorio  1 , Norma Brito  1 , Emanuel Sarinho  1
Affiliations

Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment

Viviane Gouveia et al. Cardiol Res. 2016 Jun.

Abstract

Background: Percutaneous coronary intervention (PCI) revolutionized treatment of coronary artery disease. Drug-eluting stents are effective and safe but their cost is high, especially for some countries. The primary objective was to evaluate the safety of methotrexate (MTX) in patients who underwent PCI and the secondary goal was to evaluate the possibility that MTX has an impact on restenosis.

Methods: This was a transversal, prospective and descriptive study that recruited 16 patients in whom PCI was planned. MTX was administered to patients at a dose of 5 mg/week for 2 weeks before PCI and 8 weeks after PCI. Bare-metal stent (BMS) deployment was performed according to standard practice. Patients were monitored clinically every 15 days during the first 2 months after the procedure and monthly until 9 months after PCI.

Results: There were no immediate or late complications associated with PCI. Adverse events and side effects due to MTX occurred in three patients (prevalence 18.7%). These side effects are classified as minor complications. MTX was not discontinued due to these side effects. There were no reported cases of clinical restenosis.

Conclusions: MTX was safe in the study population and raised the possibility that a low-cost drug may have positive effects on restenosis after BMS implantation. However, studies with larger sample sizes and other imagine modalities (intravascular ultrasound and/or optical coherence tomography) are required to confirm this hypothesis.

Keywords: Coronary artery disease; Methotrexate; Restenosis; Stent.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kubo S, Kadota K, Otsuru S, Hasegawa D, Habara S, Tada T, Tanaka H. et al. Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure. EuroIntervention. 2015;10(9):e1, 8. doi: 10.4244/EIJV10I9A180. - DOI - PubMed
    1. Almeida RMS. Myocardial revascularization: comparative cost study between conventional coronary bypass and percutaneous transluminal coronary angioplasty. Rev Bras Cir Cardiovasc. 2005;20:142–148. doi: 10.1590/S0102-76382005000200009. - DOI
    1. Koskinas KC, Chatzizisis YS, Antoniadis AP, Giannoglou GD. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol. 2012;59(15):1337–1349. doi: 10.1016/j.jacc.2011.10.903. - DOI - PubMed
    1. Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther. 2011;29(3):190–198. doi: 10.1111/j.1755-5922.2010.00155.x. - DOI - PubMed
    1. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH. et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297(18):1992–2000. doi: 10.1001/jama.297.18.1992. - DOI - PubMed

LinkOut - more resources